Lesinurad in hyperuricaemia of gout: a profile of its use in the EU
- Medicine, BiologyDrugs & Therapy Perspectives
The addition of once-daily oral lesinurad enabled many patients to achieve target sUA levels, and improved clinical parameters (e.g. tophus number/size) in the long term.
Environmental factors and risk of gout.
- Environmental ScienceEnvironmental research
Management of gout in older people
- MedicineJournal of Pharmacy Practice and Research
Despite the availability of effective therapy, gout remains undertreated, with maintenance of urate‐lowering therapy a major challenge, and education of patients and health professionals is essential to improve adherence to therapy.
IL-17A neutralizing antibody regulates monosodium urate crystal-induced gouty inflammation.
- BiologyPharmacological research
The Role of the Intestine in the Development of Hyperuricemia
- Medicine, BiologyFrontiers in Immunology
The effects of intestinal uric Acid transporters and intestinal flora on uric acid excretion are reviewed, and new ideas for the treatment of hyperuricemia and gout are provided.
Urate crystal deposition, prevention and various diagnosis techniques of GOUT arthritis disease: a comprehensive review
- MedicineHealth Inf. Sci. Syst.
Imaging procedures have ended up being helpful for location of urate statement, even before the primary clinical indications, empowering the assessment of the degree of testimony and giving target estimation of precious stone exhaustion amid urate-bringing down treatment.
The Use of Cryotherapy in the Gout Pain Control: A Systematic Review
Clinical signs of gouty arthritis occur as a result of this inflammatory response to crystals, with clinical picture showing local symptoms of acute arthritis, such as pain.
Effect of Clinical Typing on Serum Urate Targets of Benzbromarone in Chinese Gout Patients: A Prospective Cohort Study
- MedicineFrontiers in Medicine
The increased achievement of target serum urate in the underexcretion group supports the use of a clinical hyperuricemia typing treatment strategy for gout.
Management of hyperuricemia in asymptomatic patients: A critical appraisal.
- MedicineEuropean journal of internal medicine
SHOWING 1-10 OF 105 REFERENCES
The changing epidemiology of gout
- MedicineNature Clinical Practice Rheumatology
Osteoarthritis, which is thought to predispose patients to monosodium urate crystal deposition in their joints, is becoming more prevalent as a consequence of increased longevity.
To Treat or Not to Treat (to Target) in Gout
- MedicineAnnals of Internal Medicine
It is suggested that a reactive treat- to-avoid-symptoms approach may be a reasonable strategy with ULT instead of a proactive treat-to-target strategy because the latter has not been adequately tested.
Gout: optimizing treatment to achieve a disease cure
- MedicineTherapeutic advances in chronic disease
The main aim in gout is to lower serum uric acid levels to a pre-established target; there are different urate-lowering drugs (xanthine oxidase inhibitors, uricosurics and uricases) through which this can be achieved.
Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
- MedicineArthritis and rheumatism
Serum urate levels should be lowered enough to promote dissolution of urate deposits in patients with tophaceous gout, and allopurinol and benzbromarone are equally effective when optimal serum Urate levels are achieved during therapy.
Global epidemiology of gout: prevalence, incidence and risk factors
- MedicineNature Reviews Rheumatology
Data from epidemiological studies from diverse regions of the world are synthesized to depict the geographic variation in gout prevalence and incidence, and indicate that the distribution of gout is uneven across the globe, with prevalence being highest in Pacific countries.
Why does the gout attack stop? A roadmap for the immune pathogenesis of gout
- MedicineRMD Open
Reactive oxygen species are essential for forming NETs and for allowing the resolution of inflammation in gout, since tophi are composed ofNETs and densely packed MSU crystals.
Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy
- Biology, MedicineProceedings of the National Academy of Sciences
Data show that Glut9 plays a major role in urate homeostasis by its dual role inUrate handling in the kidney and uptake in the liver, as well as, by incompletely understood renal processes of reabsorption and secretion.
Gout and Quality of Life
- MedicineThe Journal of Rheumatology
The majority of gout patients under the care of physicians are not adequately managed with currently available anti-gout therapies and have become the primary target for quality improvement of care, including new drug development.
Predicting allopurinol response in patients with gout.
- MedicineBritish journal of clinical pharmacology
Contrary to current guidelines, the model predicted that allopurinol dose requirements were determined primarily by differences in body size and diuretic use, which was found to be significant covariates.
The genetics of gout: towards personalised medicine?
- Medicine, BiologyBMC Medicine
Genetic data may inform assessment of disease prognosis in individuals with hyperuricaemia or established gout, personalised lifestyle advice, selection and dosing of urate-lowering therapy, and prevention of serious medication adverse effects.